RTTNews | Apr 9, 2021 10:13AM EDT

10:13 Friday, April 9, 2021 (RTTNews.com) - Shares of clinical-stage immuno-oncology company Affimed N.V. (AFMD) are up more than 20% Friday morning after the company announced positive initial data from the Phase 1 study evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed's innate cell engager (ICE), AFM13 in solid tumors.

Affimed said all four patients experienced significant disease reduction, with two complete responses and two partial responses, with an objective response rate of 100%.

Data from the study conducted at The University of Texas MD Anderson Cancer Center were presented at the virtual American Association for Cancer Research (AACR) Annual Meeting.

"These initial results indicate AFM13 may have the potential to help NK cells target and destroy cancer cells. We plan to continue to develop and customize approaches that leverage the unique and differentiating features of our ICE molecules in combination with adoptive NK cell transfer to provide options for treating a variety of hematologic and solid tumors" said Andreas Harstrick, Chief Medical Officer of Affimed.

AFMD touched a new high of $10.70 this morning, before declining to trade at $9.54 currently.

Read the original article on RTTNews ( https://www.rttnews.com/3183875/stock-alert-affimed-trading-20-higher.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved